Sign in
Author
|
Conference
|
Journal
|
Organization
|
Year
|
DOI
Look for results that meet for the following criteria:
since
equal to
before
between
and
Search in all fields of study
Limit my searches in the following fields of study
Agriculture Science
Arts & Humanities
Biology
Chemistry
Computer Science
Economics & Business
Engineering
Environmental Sciences
Geosciences
Material Science
Mathematics
Medicine
Physics
Social Science
Multidisciplinary
Keywords
(5)
Brain Tumor
Cancer Vaccine
Cell Trafficking
Engineering Polymers
Immune Response
Subscribe
Academic
Publications
Biomaterial-Based Vaccine Induces Regression of Established Intracranial Glioma in Rats
Biomaterial-Based Vaccine Induces Regression of Established Intracranial Glioma in Rats,10.1007/s11095-010-0361-x,Pharmaceutical Research,Omar A. Ali,
Edit
Biomaterial-Based Vaccine Induces Regression of Established Intracranial Glioma in Rats
BibTex
|
RIS
|
RefWorks
Download
Omar A. Ali
,
Ed Doherty
,
William J. Bell
,
Tracie Fradet
,
Jebecka Hudak
,
Marie-Therese Laliberte
,
David J. Mooney
,
Dwaine F. Emerich
Purpose The prognosis for glioma patients is poor, and development of new treatments is critical. Previously, we engineered polymer-based vaccines that control GM-CSF, CpG-oligonucleotide, and tumor-lysate presentation to regulate immune
cell trafficking
and activation, which promoted potent immune responses against peripheral tumors. Here, we extend the use of this system to glioma. Methods Rats were challenged with an intracranial injection of glioma cells followed (1 week) by administration of the polymeric vaccine (containing GM-CSF, CpG, and tumor-lysate) in the tumor bed. Control rats were treated with blank matrices, matrices with GM-CSF and CpG, or intra-tumoral bolus injections of GM-CSF, CpG, and tumor lysate. Rats were monitored for survival and tested for neurological function. Results Survival studies confirmed a benefit of the polymeric vaccine as 90% of vaccinated rats survived for >100 days. Control rats exhibited minimal benefit. Motor tests revealed that vaccination protected against the loss of forelimb use produced by glioma growth. Histological analysis quantitatively confirmed a robust and rapid reduction in tumor size. Long-term immunity was confirmed when 67% of survivors also survived a second glioma challenge. Conclusions These studies extend previous reports regarding this approach to tumor therapy and justify further development for glioma treatment.
Journal:
Pharmaceutical Research - PHARMACEUT RES
, vol. 28, no. 5, pp. 1074-1080, 2011
DOI:
10.1007/s11095-010-0361-x
Cumulative
Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
(
www.springerlink.com
)
(
www.springerlink.com
)
References
(22)
Brain and Other Central Nervous System Cancers: Recent Trends in Incidence and Mortality
(
Citations: 104
)
Julie M. Legler
,
Lynn A. Gloeckler Ries
,
Malcolm A. Smith
,
Joan L. Warren
,
Ellen F. Heineman
,
Richard S. Kaplan
,
Martha S. Linet
Published in 1999.
Brain Tumor Immunotherapy with Type1 Polarizing Strategies
(
Citations: 8
)
Hideho Okada
Journal:
Annals of The New York Academy of Sciences - ANN N Y ACAD SCI
, vol. 1174, no. 1, pp. 18-23, 2009
TLR ligands in the local treatment of established intracerebral murine gliomas
(
Citations: 15
)
Oliver M. Grauer
,
Johan W. Molling
,
Erik Bennink
,
Liza W. J. Toonen
,
Roger P. M. Sutmuller
,
Stefan Nierkens
,
Gosse J. Adema
Journal:
Journal of Immunology - J IMMUNOL
, pp. 6720-6729, 2008
Immunotherapy of diffuse gliomas: biological background, current status and future developments
(
Citations: 9
)
Oliver M. Grauer
,
Pieter Wesseling
,
Gosse J. Adema
Journal:
Brain Pathology - BRAIN PATHOL
, vol. 19, no. 4, pp. 674-693, 2009
Taking dendritic cells into medicine
(
Citations: 371
)
Ralph M. Steinman
,
Jacques Banchereau
Journal:
Nature
, vol. 449, no. 7161, pp. 419-426, 2007